ARHGAP25

Across TCGA pan-cancer cohorts, ARHGAP25 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ARHGAP25 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ARHGAP25 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGAP25 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, UCEC, and LUAD are the cancer types where ARHGAP25 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.123	0.715	<.001	36	view →
UCEC	DFS	Median	II,III,IV	0.937	0.433	.011	24	view →
LUAD	OS	Median	II,III,IV	0.314	0.717	<.001	24	view →
SKCM	DFS	Median	II,III,IV	0.228	0.598	.011	12	view →
BLCA	DFS	Median	III,IV	0.230	0.575	.044	9	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
ESCA	OS	Median	All	0.176	0.680	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ARHGAP25–SCLC (OS)

Open the SCLC breakdown →